Immunology of Sepsis

Area of Science:

• Immunology
• Critical Care Medicine

Background:

• Sepsis involves immune dysregulation across pathogen recognition, inflammation, and immune paralysis phases.
• Key immune cells like macrophages and T cells, along with mediators such as cytokines, are central to these processes.
• Current sepsis treatment trials face challenges due to patient heterogeneity.

Purpose of the Study:

• To elucidate the immunologic phases and cellular players in sepsis-related immune dysregulation.
• To highlight the role of immunologic biomarkers in understanding sepsis.
• To propose improved trial designs for sepsis immunomodulatory therapies.

Main Methods:

• Review of immune cell functions and mediator roles in sepsis.
• Analysis of immune cell populations and cytokine/chemokine profiles.
• Examination of past clinical trial outcomes in sepsis.

Main Results:

• Sepsis progression involves distinct but overlapping immune phases.
• Epithelial cells, neutrophils, monocytes, macrophages, and T cells are critical immune participants.
• Cytokines and chemokines serve as measurable immunologic biomarkers.

Conclusions:

• Immune dysregulation in sepsis is a multi-phase process involving specific cell types and mediators.
• Patient selection for clinical trials must consider specific immunologic profiles for therapeutic success.
• Refined trial designs focusing on immunologic targets hold promise for effective sepsis therapies.